Community Howard Regional Health
Claim this profile,
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Adenocarcinoma
233 reported clinical trials
7 medical researchers
Summary
Community Howard Regional Health is a medical facility located in undefined, undefined. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Community Howard Regional Health is involved with conducting 233 clinical trials across 294 conditions. There are 7 research doctors associated with this hospital, such as Daniel W. Weed, Shih J. Wei, Annette M. Moore, and Pablo M. Bedano.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 positive
ER positive
ER negative
Top PIs
Daniel W. WeedCommunity Cancer Center South6 years of reported clinical research
Studies Breast Cancer
Studies Lung Cancer
7 reported clinical trials
16 drugs studied
Shih J. WeiCommunity Cancer Center East4 years of reported clinical research
Studies Cancer
Studies Breast Cancer
3 reported clinical trials
6 drugs studied
Annette M. MooreCommunity Cancer Center South6 years of reported clinical research
Studies Multiple Myeloma
Studies Plasma Cell Neoplasms
2 reported clinical trials
6 drugs studied
Pablo M. BedanoCommunity Cancer Center South10 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
2 reported clinical trials
2 drugs studied
Clinical Trials running at Community Howard Regional Health
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Colorectal Cancer
Laryngeal Cancer
Cancer
Oropharyngeal Carcinoma
ALK Gene Rearrangement
Squamous Cell Carcinoma
Oral Cavity Carcinoma
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Community Howard Regional Health?
Community Howard Regional Health is a medical facility located in undefined, undefined. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Community Howard Regional Health is involved with conducting 233 clinical trials across 294 conditions. There are 7 research doctors associated with this hospital, such as Daniel W. Weed, Shih J. Wei, Annette M. Moore, and Pablo M. Bedano.